• Insider Moves: Palatin, Dollar Tree, Coupang, Coherent, Bausch TipRanks Sat, 21 Jun 2025 13:09:32 GMT
• palatin technologies announces closing of reduced public offering (pr newswire) Aktiellt Fri, 20 Jun 2025 09:33:26 GMT
• Palatin Technologies Executives Make Massive Stock Purchases! TipRanks Tue, 17 Jun 2025 07:00:00 GMT
• palatin technologies (pali) teams up with key managers for investment strategy | pali stock news GuruFocus Tue, 27 May 2025 07:00:00 GMT
• Palatin Technologies, Inc. (AMEX:PTN) Q3 2025 Earnings Call Transcript MSN Sun, 25 May 2025 21:02:46 GMT
• palatin technologies, inc. (amex:ptn) q3 2025 earnings call transcript MSN Thu, 22 May 2025 02:38:44 GMT
• palatin technologies, inc. (amex:ptn) q3 2025 earnings call transcript Insider Monkey Tue, 20 May 2025 07:00:00 GMT
• palatin technologies (nyse:ptn) coverage initiated by analysts at stocknews.com Defense World Tue, 20 May 2025 07:00:00 GMT
• moderate dry eye market growth to accelerate in forecast period (2023-2032), delveinsight analyzes | mc2 therapeutics, palatin tec... The Globe and Mail Thu, 15 May 2025 14:46:00 GMT
• palatin reports fiscal year 2025 third quarter results and business update The Malaysian Reserve Thu, 15 May 2025 10:06:11 GMT
• Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... Yahoo Finance Thu, 15 May 2025 07:00:00 GMT
• earnings call transcript: palatin’s q3 fy2025 shows narrower loss by investing.com Investing.com Nigeria Thu, 15 May 2025 02:19:53 GMT
• Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update PR Newswire Wed, 14 May 2025 07:00:00 GMT
• Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss Investing.com Wed, 14 May 2025 07:00:00 GMT
• palatin's new obesity drug shows 4.4% weight loss when combined with popular glp-1 treatment Stock Titan Wed, 14 May 2025 07:00:00 GMT
• palatin technologies (ptn) to release quarterly earnings on wednesday Defense World Wed, 14 May 2025 07:00:00 GMT
• palatin technologies (nyse:ptn) coverage initiated by analysts at stocknews.com Defense World Tue, 13 May 2025 07:09:58 GMT
• palatin technologies director robert deveer buys $10,180 in stock by investing.com Investing.com Nigeria Tue, 13 May 2025 02:10:03 GMT
• Palatin Technologies director Robert DeVeer buys $10,180 in stock Investing.com Mon, 12 May 2025 07:00:00 GMT
• palatin technologies (nyse:ptn) coverage initiated by analysts at stocknews.com Defense World Mon, 12 May 2025 07:00:00 GMT
• palatin reveals potential diabetic retinopathy treatments Investing.com Sat, 10 May 2025 10:12:31 GMT
• biotech alert: searches spiking for these stocks today Yahoo Finance Sat, 10 May 2025 07:00:00 GMT
• two new option listings and two option delistings on may 9th TipRanks Fri, 09 May 2025 15:24:45 GMT
• palatin expects $11.5m financing to cure nyse american delisting notice MSN Fri, 09 May 2025 08:21:18 GMT
• Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 PR Newswire Fri, 09 May 2025 07:00:00 GMT
• Palatin Technologies (PTNT): A High-Risk Gamble Amid Financial Strains and Regulatory Setbacks AInvest Fri, 09 May 2025 07:00:00 GMT
• palatin technologies announces closing of reduced public offering Financial Times Fri, 09 May 2025 07:00:00 GMT
• palatin unveils promising preclinical data for diabetic retinopathy treatments at arvo 2025 Nasdaq Fri, 09 May 2025 07:00:00 GMT
• palatin reveals potential diabetic retinopathy treatments Investing.com Fri, 09 May 2025 07:00:00 GMT
• Palatin Technologies Announces Closing of Reduced Public Offering PR Newswire Thu, 08 May 2025 07:00:00 GMT
• Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 Yahoo Finance Thu, 08 May 2025 07:00:00 GMT
• Palatin Technologies (PTN) Reveals Promising Phase 3 Study Results for PL9643 in Dry Eye Disease | PTN Stock News GuruFocus Thu, 08 May 2025 07:00:00 GMT
• ptn faces delisting from nyse american, shares transition to otc market | ptn stock news GuruFocus Thu, 08 May 2025 07:00:00 GMT
• palatin technologies announces transition to otc pink following nyse american delisting notice | ptn stock news GuruFocus Thu, 08 May 2025 07:00:00 GMT
• Palatin Technologies Announces Pricing of up to $23 Million Public Offering PR Newswire Wed, 07 May 2025 07:00:00 GMT
• Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice Stock Titan Wed, 07 May 2025 07:00:00 GMT
• Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice PR Newswire Wed, 07 May 2025 07:00:00 GMT
• Palatin Technologies sets terms for $23 million offering Investing.com Wed, 07 May 2025 07:00:00 GMT
• NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) Business Wire Wed, 07 May 2025 07:00:00 GMT
• Palatin Technologies faces delisting from NYSE American due to low stock price Investing.com Wed, 07 May 2025 07:00:00 GMT
• Palatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug Development Nasdaq Wed, 07 May 2025 07:00:00 GMT
• palatin secures $11.5 million to tackle nyse delisting, boost obesity drugs Investing.com Canada Wed, 07 May 2025 07:00:00 GMT
• palatin technologies stock trading halted pending material announcement MarketScreener Wed, 07 May 2025 07:00:00 GMT
• palatin (ptn) aims to address delisting concerns with public offering | ptn stock news GuruFocus Wed, 07 May 2025 07:00:00 GMT
• palatin (ptn) unveils promising data for glaucoma treatment cand GuruFocus Mon, 05 May 2025 15:39:58 GMT
• Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Ther... PR Newswire Mon, 05 May 2025 07:00:00 GMT
• Palatin Technologies Announces Encouraging Pre-Clinical Data Of PL9588 For Glaucoma Treatment Nasdaq Mon, 05 May 2025 07:00:00 GMT
• Breakthrough Dual-Action Glaucoma Therapy Shows 25% Cell Protection in Trial Data | PTN Stock News Stock Titan Mon, 05 May 2025 07:00:00 GMT
• palatin technologies (nyse:ptn) coverage initiated at stocknews.com Defense World Sun, 04 May 2025 07:00:00 GMT
• palatin provides update from pivotal phase 3 melody-1 clinical trial TipRanks Tue, 29 Apr 2025 13:22:45 GMT
• palatin (ptn) announces promising results for pl9643 in dry eye disease study | ptn stock news GuruFocus Tue, 29 Apr 2025 13:08:52 GMT
• Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disea... PR Newswire Tue, 29 Apr 2025 07:00:00 GMT
• Palatin releases updated results from responder analyses of phase 3 MELODY-1 trial in dry eye Ophthalmology Times Tue, 29 Apr 2025 07:00:00 GMT
• first-ever complete symptom resolution: game-changing phase 3 results in $6b dry eye market Stock Titan Tue, 29 Apr 2025 07:00:00 GMT
• palatin reports positive results from responder analyses of phase 3 melody-1 study in ded Nasdaq Tue, 29 Apr 2025 07:00:00 GMT
• investor network: palatin technologies, inc. to host earnings call ACCESS Newswire Sun, 27 Apr 2025 17:45:37 GMT
• nyse to commence delisting proceedings against solo brands, inc. (dtc) Business Wire Tue, 22 Apr 2025 20:12:00 GMT
• palatin concludes phase ii trial of combination therapy for obesity MSN Tue, 22 Apr 2025 18:49:11 GMT
• palatin’s obesity study shows promise in appetite control by investing.com Investing.com Canada Fri, 18 Apr 2025 03:45:17 GMT
• dry eye disease market growth projections 2024-2034: delveinsight analysis | palatin technologies, novaliq, mc2 therapeutics The Globe and Mail Thu, 17 Apr 2025 13:56:30 GMT
• palatin (ptn) reports positive phase 2 study results for obesity treatment | ptn stock news GuruFocus Thu, 17 Apr 2025 12:01:39 GMT
• Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide PR Newswire Thu, 17 Apr 2025 07:00:00 GMT
• Breakthrough Obesity Treatment Shows 71% Appetite Control, Blocks Post-Treatment Weight Rebound Stock Titan Thu, 17 Apr 2025 07:00:00 GMT
• Palatin’s obesity study shows promise in appetite control Investing.com Thu, 17 Apr 2025 07:00:00 GMT
• palatin appeals nyse american notice of delisting Kilgore News Herald Tue, 15 Apr 2025 12:49:58 GMT
• palatin technologies (ptn) appeals nyse delisting decision | ptn stock news GuruFocus Tue, 15 Apr 2025 05:50:48 GMT
• Palatin Launches Bold Defense Against NYSE Delisting: Multi-Strategy Rescue Plan Revealed Stock Titan Mon, 14 Apr 2025 07:00:00 GMT
• Palatin Appeals NYSE Delisting, Pursues Financing And Partnerships To Regain Compliance Nasdaq Mon, 14 Apr 2025 07:00:00 GMT
• palatin contests nyse american delisting notice by investing.com Investing.com Canada Mon, 14 Apr 2025 07:00:00 GMT
• palatin appeals nyse american notice of delisting | ptn stock ne GuruFocus Mon, 14 Apr 2025 07:00:00 GMT
• palatin technologies (ptn) appeals nyse delisting decision | ptn stock news GuruFocus Mon, 14 Apr 2025 07:00:00 GMT
• stock slump: eyewear innovator and tech firms face market hits Finimize Sat, 12 Apr 2025 05:51:15 GMT
• Stock Slump: Eyewear Innovator And Tech Firms Face Market Hits Finimize Fri, 11 Apr 2025 19:37:59 GMT
• palatin technologies (ptn) faces nyse american delisting proceedings GuruFocus Fri, 11 Apr 2025 16:18:09 GMT
• palatin (ptn) faces delisting proceedings from nyse american | p GuruFocus Fri, 11 Apr 2025 16:07:43 GMT
• palatin to present positive phase 2b data for melanocortin agoni GuruFocus Fri, 11 Apr 2025 07:14:02 GMT
• Palatin Technologies faces delisting over equity shortfall The Pharma Letter Fri, 11 Apr 2025 07:00:00 GMT
• Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX Stocktwits Fri, 11 Apr 2025 07:00:00 GMT
• palatin concludes phase ii trial of combination therapy for obesity MSN Thu, 10 Apr 2025 21:17:25 GMT
• palatin technologies shares fall as it receives nyse american delisting notice MSN Thu, 10 Apr 2025 20:31:17 GMT
• palatin receives nyse american notice of delisting, plans to appeal TipRanks Thu, 10 Apr 2025 20:07:45 GMT
• 2025-04-10 | palatin to present positive phase 2b data for melanocortin agonist in diabetic kidney disease at the national kidney ... Stockhouse Thu, 10 Apr 2025 11:30:00 GMT
• Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal PR Newswire Thu, 10 Apr 2025 07:00:00 GMT
• Palatin Technologies faces potential NYSE American delisting Investing.com Thu, 10 Apr 2025 07:00:00 GMT
• Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Sp... PR Newswire Thu, 10 Apr 2025 07:00:00 GMT
• palatin technologies reports positive data from phase 2b breakout study Nasdaq Thu, 10 Apr 2025 07:00:00 GMT
• nyse american to commence delisting proceedings against palatin technologies, inc. (ptn) Business Wire Thu, 10 Apr 2025 07:00:00 GMT
• nyse american moves to delist palatin technologies: company fighting back Stock Titan Thu, 10 Apr 2025 07:00:00 GMT
• palatin reports promising kidney disease treatment results Investing.com Thu, 10 Apr 2025 07:00:00 GMT
• palatin technologies (ptn) faces nyse american delisting proceedings GuruFocus Thu, 10 Apr 2025 07:00:00 GMT
• breakthrough: new drug shows 71% success rate in diabetic kidney disease trial Stock Titan Thu, 10 Apr 2025 07:00:00 GMT
• palatin (ptn) faces delisting proceedings from nyse american | p GuruFocus Thu, 10 Apr 2025 07:00:00 GMT
• stock slump: eyewear innovator and tech firms face market hits Finimize Wed, 09 Apr 2025 07:00:00 GMT
• dry eye disease market to expand significantly by 2034, states openPR.com Wed, 09 Apr 2025 07:00:00 GMT
• palatin says bmt-801 phase 2 obesity study met primary endpoint TipRanks Mon, 31 Mar 2025 13:45:28 GMT
• Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity ... PR Newswire Mon, 31 Mar 2025 07:00:00 GMT
• Palatin touts synergistic weight loss effect with MC4R agonist, Zepbound combo FirstWord Pharma Mon, 31 Mar 2025 07:00:00 GMT
• Breakthrough Obesity Treatment: New Drug Combo Achieves 4.4% Weight Loss in Clinical Trial Stock Titan Mon, 31 Mar 2025 07:00:00 GMT
• Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight Benzinga Mon, 31 Mar 2025 07:00:00 GMT
• palatin technologies’ uc treatment shows remarkable 78% clinical response rate in phase 2 topline data – potential game-changer fo... Barchart.com Mon, 31 Mar 2025 07:00:00 GMT
• palatin reported promising results in trial for ulcerative colitis treatment MSN Sun, 30 Mar 2025 11:23:01 GMT
• palatin reported promising results in trial for ulcerative colitis treatment MSN Sat, 29 Mar 2025 00:17:41 GMT
• palatin technologies' ulcerative colitis drug candidate shows positive results in phase 2 study MarketScreener Fri, 28 Mar 2025 14:50:56 GMT
• ptn stock touches 52-week low at $0.67 amid market challenges Investing.com UK Fri, 28 Mar 2025 13:32:00 GMT
• Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL81... PR Newswire Fri, 28 Mar 2025 07:00:00 GMT
• Palatin’s UC therapy prompts clinical remission in a third of patients Clinical Trials Arena Fri, 28 Mar 2025 07:00:00 GMT
• palatin’s pl8177 shows promise in ulcerative colitis study by investing.com Investing.com Australia Fri, 28 Mar 2025 07:00:00 GMT
• palatin technologies reports positive data from phase 2 study of pl8177 in ulcerative colitis Nasdaq Fri, 28 Mar 2025 07:00:00 GMT
• palatin technologies touts positive results from mid-stage study for experimental drug for ulcerative colitis, halts patients enro... Benzinga Fri, 28 Mar 2025 07:00:00 GMT
• breakthrough: novel uc treatment achieves 78% response rate, big pharma circling Stock Titan Fri, 28 Mar 2025 07:00:00 GMT
• palatin reported promising results in trial for ulcerative colitis treatment (ptn:nyse) Seeking Alpha Fri, 28 Mar 2025 07:00:00 GMT
• palatin reports ‘positive’ results from phase 2 study of pl8177 TipRanks Fri, 28 Mar 2025 07:00:00 GMT
• palatin technologies (nyseamerican:ptn) share price passes above 200 day moving average – what’s next? Defense World Thu, 27 Mar 2025 07:28:45 GMT
• palatin technologies' obesity drug receives fda orphan designation; phase 2 results imminent (nyse: ptn) openPR.com Thu, 27 Mar 2025 07:00:00 GMT
• Palatin Drug Gets FDA’s Orphan Nod for Rare Type of Obesity Inside Precision Medicine Wed, 26 Mar 2025 07:00:00 GMT
• US FDA grants orphan drug status to Palatin’s obesity treatment PL7737 Pharmaceutical Business review - Wed, 26 Mar 2025 07:00:00 GMT
• palatin’s dual blockbuster potential: obesity and ulcerative colitis results expected within days NewsBlaze Tue, 25 Mar 2025 12:31:48 GMT
• palatin reports second quarter fiscal year 2025 financial results and provides business update The Victoria Advocate Tue, 25 Mar 2025 12:17:44 GMT
• Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency PR Newswire Tue, 25 Mar 2025 07:00:00 GMT
• breakthrough: fda backs palatin's novel oral drug for rare genetic obesity condition Stock Titan Tue, 25 Mar 2025 07:00:00 GMT
• palatin’s obesity drug gains fda orphan status by investing.com Investing.com Canada Tue, 25 Mar 2025 07:00:00 GMT
• palatin stock gains on fda orphan drug status (ptn:nyse) Seeking Alpha Tue, 25 Mar 2025 07:00:00 GMT
• palatin technologies (nyseamerican:ptn) share price passes above 200 day moving average – time to sell? Defense World Wed, 19 Mar 2025 07:50:37 GMT
• Here's Why Palatin Technologies (PTN) Is a Great 'Buy the Bottom' Stock Now Yahoo Finance Thu, 13 Mar 2025 07:00:00 GMT
• palatin technologies (nyseamerican:ptn) shares pass above two hundred day moving average – time to sell? Defense World Tue, 11 Mar 2025 07:00:00 GMT
• palatin reports second quarter fiscal year 2025 financial results and provides business update GuruFocus.com Sun, 09 Mar 2025 12:47:52 GMT
• palatin awaits data release from phase 2 trial of bremelanotide-tirzepatide combo in weight loss RTTNews Mon, 24 Feb 2025 08:05:00 GMT
• palatin secures $4.7 million in stock and warrant sale by investing.com Investing.com Nigeria Thu, 20 Feb 2025 09:05:27 GMT
• hc wainwright cuts palatin technologies (nyseamerican:ptn) price target to $7.00 Armenian Reporter Sun, 16 Feb 2025 16:07:35 GMT
• palatin reports second quarter fiscal year 2025 financial results and provides business update br.ADVFN.com Sun, 16 Feb 2025 06:39:28 GMT
• hc wainwright issues pessimistic forecast for palatin technologies (nyseamerican:ptn) stock price Defense World Sat, 15 Feb 2025 08:00:00 GMT
• palatin technologies inc (ptn) q2 2025 earnings call highlights: strategic advances amid ... Yahoo Finance Fri, 14 Feb 2025 08:00:00 GMT
• palatin technologies, inc. (amex:ptn) q2 2025 earnings call transcript Insider Monkey Fri, 14 Feb 2025 08:00:00 GMT
• Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire Thu, 13 Feb 2025 08:00:00 GMT
• Palatin Technologies Inc (PTN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... Yahoo Finance Thu, 13 Feb 2025 08:00:00 GMT
• earnings call transcript: palatin technologies q2 fy2025 sees stock surge Investing.com Thu, 13 Feb 2025 08:00:00 GMT
• palatin technologies q2 25 earnings conference call at 11:00 am et Nasdaq Thu, 13 Feb 2025 08:00:00 GMT
• palatin slashes quarterly losses 70%, obesity drug trial results imminent Stock Titan Thu, 13 Feb 2025 08:00:00 GMT
• palatin to report second quarter fiscal year 2025 results; teleconference and webcast to be held on february 13, 2025 Finansavisen Thu, 13 Feb 2025 08:00:00 GMT
• palatin to report second quarter fiscal year 2025 results; teleconference and webcast to be held on february 13, 2025 BioSpace Tue, 11 Feb 2025 08:00:00 GMT
• palatin technologies (ptn) expected to post earnings on wednesday Defense World Tue, 11 Feb 2025 08:00:00 GMT
• a look at palatin technologies inc (ptn) shares in the recent past indicates growth SETE News Mon, 10 Feb 2025 14:33:29 GMT
• palatin to report second quarter fiscal year 2025 results; teleconference and webcast to be held on february 13, 2025 Yahoo Finance Mon, 10 Feb 2025 08:00:00 GMT
• palatin (ptn) q2 earnings: strategic update & pipeline progress - key details coming feb 13 Stock Titan Mon, 10 Feb 2025 08:00:00 GMT
• palatin technologies’ (ptn) buy rating reiterated at hc wainwright Defense World Mon, 10 Feb 2025 08:00:00 GMT
• palatin announces $4.7 million registered direct offering and concurrent private placement Nasdaq Sat, 08 Feb 2025 11:53:47 GMT
• ptn - palatin technologies, inc. latest stock news & market updates StockTitan Sat, 08 Feb 2025 02:35:13 GMT
• palatin technologies inc [ptn] stock for 8,274 usd was sold by wills stephen t Knox Daily Fri, 07 Feb 2025 20:33:18 GMT
• palatin to sell 4.69m shares at $1.00 in registered direct offering TipRanks Fri, 07 Feb 2025 13:48:36 GMT
• Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement PR Newswire Fri, 07 Feb 2025 08:00:00 GMT
• Palatin concludes Phase II trial of combination therapy for obesity Clinical Trials Arena Fri, 07 Feb 2025 08:00:00 GMT
• palatin's strategic $4.7m healthcare investment deal: inside the critical financing terms Stock Titan Fri, 07 Feb 2025 08:00:00 GMT
• palatin secures $4.7 million in stock and warrant sale Investing.com Fri, 07 Feb 2025 08:00:00 GMT
• palatin finishes phase 2 trial in obesity treatment study by investing.com Investing.com Nigeria Fri, 07 Feb 2025 06:24:49 GMT
• Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide PR Newswire Thu, 06 Feb 2025 08:00:00 GMT
• obesity treatment breakthrough? palatin's novel glp-1 combo trial wraps up with massive patient interest Stock Titan Thu, 06 Feb 2025 08:00:00 GMT
• palatin finishes phase 2 trial in obesity treatment study Investing.com Thu, 06 Feb 2025 08:00:00 GMT
• ptn’s price-to-sales ratio: a comparative analysis with its peers US Post News Tue, 04 Feb 2025 17:26:40 GMT
• palatin technologies inc (ptn) stock: what the analysts are saying The News Heater Tue, 04 Feb 2025 14:37:34 GMT
• ptn’s market quandary: decoding the ups and downs of 2023 The InvestChronicle Tue, 04 Feb 2025 14:20:58 GMT
• market watch: palatin technologies inc (ptn)’s noteworthy drop, closing at 0.80 The Dwinnex Tue, 04 Feb 2025 12:43:20 GMT
• palatin technologies (nyseamerican:ptn) earns “buy” rating from hc wainwright Defense World Thu, 30 Jan 2025 08:00:00 GMT
• palatin gears up for obesity treatment trials in 2025 by investing.com Investing.com Canada Wed, 29 Jan 2025 10:34:45 GMT
• Palatin Provides Update on Anticipated 2025 Corporate Milestones PR Newswire Tue, 28 Jan 2025 08:00:00 GMT
• palatin's game-changing obesity drug strategy takes aim at 67% treatment dropout rate Stock Titan Tue, 28 Jan 2025 08:00:00 GMT
• freya pharma solutions strengthens leadership with appointment of distinguished supervisory board GlobeNewswire Tue, 28 Jan 2025 08:00:00 GMT
• palatin spikes as fda clears mid-stage trial for weight loss therapy MSN Tue, 28 Jan 2025 01:33:41 GMT
• palatin starts phase 2 obesity study of bremelanotide with zepbound MSN Sun, 26 Jan 2025 13:48:10 GMT
• hb wealth management llc has $127,000 stock position in palatin technologies, inc. (nyseamerican:ptn) Defense World Sun, 26 Jan 2025 08:00:00 GMT
• palatin technologies (nyseamerican:ptn) shares cross above 200-day moving average – what’s next? Defense World Fri, 24 Jan 2025 08:00:00 GMT
• palatin technologies inc (amex: ptn) analysts expect it could climb 93.76% from current levels. Stocks Register Mon, 20 Jan 2025 14:34:19 GMT
• thinking about buying stock in medavail holdings, trio-tech international, palatin technologies, flexshopper, or silicom? Marketscreener.com Thu, 26 Dec 2024 03:44:29 GMT
• fda confirms acceptability of palatin's remaining phase 3 pivota GuruFocus.com Sun, 22 Dec 2024 23:28:08 GMT
• palatin technologies (nyseamerican:ptn) earns “buy” rating from hc wainwright Defense World Sat, 21 Dec 2024 08:00:00 GMT
• palatin reports positive phase 2b results in diabetic nephropathy Yahoo Finance Fri, 20 Dec 2024 08:00:00 GMT
• palatin announces positive phase iib breakout study results in p GuruFocus.com Fri, 20 Dec 2024 07:16:30 GMT
• first patient dosed in phase 2 clinical study of palatin's breme GuruFocus.com Thu, 19 Dec 2024 19:16:14 GMT
• Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy PR Newswire Thu, 19 Dec 2024 08:00:00 GMT
• palatin reports positive phase 2b results in type 2 diabetic nephropathy OutSourcing-Pharma.com Thu, 19 Dec 2024 08:00:00 GMT
• palatin's bremelanotide shows promising phase 2b results for diabetic kidney disease treatment StockTitan Thu, 19 Dec 2024 08:00:00 GMT
• palatin technologies announces warrant exercise for ~$3.4m gross proceeds MSN Wed, 18 Dec 2024 11:57:33 GMT
• palatin announces exercise of warrants for approximately $3.4 million gross proceeds The Eastern Progress Online Tue, 17 Dec 2024 19:37:32 GMT
• palatin technologies announces warrant exercise for ~$3.4m gross proceeds MSN Mon, 16 Dec 2024 15:35:44 GMT
• palatin announces exercise of warrants for approximately $3.4 million gross proceeds PR Newswire Mon, 16 Dec 2024 08:00:00 GMT
• palatin technologies secures $3.4m through strategic warrant exercise deal, issues new warrants StockTitan Mon, 16 Dec 2024 08:00:00 GMT
• palatin to report fourth quarter and fiscal year end 2024 results The Eastern Progress Online Thu, 12 Dec 2024 05:59:24 GMT
• palatin to report fourth quarter and fiscal year end 2024 results The Eastern Progress Online Wed, 11 Dec 2024 22:25:01 GMT
• palatin to report fourth quarter and fiscal year end 2024 results The Eastern Progress Online Sat, 07 Dec 2024 01:06:05 GMT
• palatin technologies (bue:ptn) financial strength : 4 (as of sep. 2024) GuruFocus.com Thu, 05 Dec 2024 13:56:23 GMT
• thinking about buying stock in medavail holdings, trio-tech inte GuruFocus.com Wed, 04 Dec 2024 09:42:15 GMT
• ptn (palatin technologies) price-to-free-cash-flow : n/a (as of dec. 01, 2024) GuruFocus.com Sun, 01 Dec 2024 09:04:36 GMT
• ptn (palatin technologies) cogs-to-revenue : 0.00 (as of sep. 2024) GuruFocus.com Sat, 30 Nov 2024 08:03:14 GMT
• palatin technologies stock stays buy rated after completing phase 2 enrollment in uc trial Investing.com Tue, 26 Nov 2024 08:00:00 GMT
• palatin completes patient enrollment in phase 2 study of pl8177 TipRanks Mon, 25 Nov 2024 12:36:54 GMT
• Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerati... PR Newswire Mon, 25 Nov 2024 08:00:00 GMT
• palatin completes phase 2 enrollment for novel ulcerative colitis pill, data due q1 2025 StockTitan Mon, 25 Nov 2024 08:00:00 GMT
• palatin technologies (fra:ptn) retained earnings : €-405.08 mil (as of sep. 2024) GuruFocus.com Fri, 22 Nov 2024 09:27:23 GMT
• palatin technologies (fra:ptn) graham number : €n/a (as of sep. 2024) GuruFocus.com Fri, 22 Nov 2024 08:15:20 GMT
• palatin technologies (fra:ptn) float percentage of total sh GuruFocus.com Fri, 22 Nov 2024 04:55:21 GMT
• palatin to report first quarter fiscal year 2025 results; teleco GuruFocus.com Thu, 21 Nov 2024 21:03:43 GMT
• palatin technologies, inc. (amex:ptn) q1 2025 earnings call transcript Insider Monkey Fri, 15 Nov 2024 13:17:03 GMT
• palatin technologies inc (ptn) q1 2025 earnings call highlights: strategic shifts amid revenue ... Yahoo Finance Fri, 15 Nov 2024 08:00:00 GMT
• palatin reports first quarter fiscal year 2025 operating/financial results BioSpace Fri, 15 Nov 2024 08:00:00 GMT
• earnings call: palatin therapeutics reports q1 fiscal 2025 results by investing.com Investing.com Nigeria Thu, 14 Nov 2024 17:48:45 GMT
• palatin technologies inc (ptn) q1 2025 earnings call highlights: strategic shifts amid revenue ... Yahoo Finance Thu, 14 Nov 2024 08:00:00 GMT
• palatin reports first quarter fiscal year 2025 operating/financial results PR Newswire Thu, 14 Nov 2024 08:00:00 GMT
• palatin tech advances obesity drug trial as q1 loss widens to $7.8m StockTitan Thu, 14 Nov 2024 08:00:00 GMT
• palatin to report first quarter fiscal year 2025 results; teleco GuruFocus.com Thu, 14 Nov 2024 08:00:00 GMT
Palatin Technologies, Inc(NYSE MKT:PTN) 
Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acqui...
Website: http://www.palatin.com
Founded: 1986
Full Time Employees: 20
Sector: Healthcare
Industry: Biotechnology